MindWalk (NASDAQ:HYFT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of MindWalk (NASDAQ:HYFT) from a sell rating to a hold rating in a report issued on Saturday.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Finally, Zacks Research cut MindWalk from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.00.

MindWalk Trading Up 1.4%

NASDAQ HYFT opened at $1.41 on Friday. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. MindWalk has a 1-year low of $0.99 and a 1-year high of $3.25. The firm’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.39. The company has a market capitalization of $65.86 million, a PE ratio of -6.41 and a beta of 0.84.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. The firm had revenue of $3.03 million for the quarter. As a group, sell-side analysts anticipate that MindWalk will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MindWalk

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of MindWalk in the fourth quarter worth about $51,000. GSA Capital Partners LLP acquired a new position in shares of MindWalk during the 2nd quarter valued at about $55,000. Bridgeway Capital Management LLC acquired a new position in shares of MindWalk during the 4th quarter valued at about $91,000. Bank of Montreal Can raised its stake in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after acquiring an additional 24,500 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares in the last quarter. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.